Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Other Non Operating Income (2021 - 2025)

SAB Biotherapeutics' Other Non Operating Income history spans 5 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 78.44% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $3.1 million, up 27.77%, while the annual FY2025 figure was $3.1 million, 27.77% up from the prior year.
  • Other Non Operating Income reached $1.5 million in Q4 2025 per SABSW's latest filing, up from $765881.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $7.8 million in Q1 2022 to a low of -$69138.0 in Q2 2021.
  • Average Other Non Operating Income over 5 years is $947987.9, with a median of $475130.0 recorded in 2024.
  • Peak YoY movement for Other Non Operating Income: plummeted 61.37% in 2022, then surged 6264.31% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $3953.0 in 2021, then surged by 715.25% to $32227.0 in 2022, then soared by 948.52% to $337906.0 in 2023, then surged by 153.03% to $854997.0 in 2024, then skyrocketed by 78.44% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Other Non Operating Income are $1.5 million (Q4 2025), $765881.0 (Q3 2025), and $295630.0 (Q2 2025).